Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells

Journal of Clinical Oncology

Volumn 18, Issue 1, 2000, Pages 43-53

  Weaver, Charles H ^a   Schulman, Kevin A ^a   Wilson Relyea, Barbara ^a   Birch, Robert ^a   West, William ^a   Buckner, C Dean ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; THIOTEPA;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 0033987790     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.1.43     Document Type: Article

References (45)

1. Demirer T, Buckner CD, Bensinger WI: Optimization of peripheral blood stem cell mobilization. Stem Cells (Dayt) 14:106-116, 1996
2. Bensinger WI, Singer J, Appelbaum F, et al: Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood 81:3158-3163, 1993
3. Bensinger WI, Longin K, Appelbaum F, et al: Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): An analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 87:825-831, 1994
4. Weaver CH, Birch R, Greco FA, et al: Mobilization and harvesting of peripheral blood stem cells: A randomized dose escalation trial of filgrastim. Br J Haematol 100:338-347, 1998
5. Schwartzberg L, Birch R, Hazelton B, et al: Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor. J Hematother 1:317-327, 1992
6. Bensinger W, Appelbaum F, Rowley S, et al: Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 13:2547-2555, 1995
7. Weaver C, Zhen B, Schwartzberg L, et al: A randomized trial of mobilization of peripheral blood stem cells with cyclophosphamide, etoposide and G-CSF with or without cisplatin in patients with malignant lymphoma receiving high-dose chemotherapy. Am J Clin Oncol 21:141-150, 1998
8. Weaver CH, Schwartzberg LS, Birch R, et al: Collection of peripheral blood progenitor cells after the administration of cyclophosphamide, etoposide and granulocyte-colony stimulating factor: An analysis of 497 patients. Transfusion 37:896-903, 1997
9. Weaver CH, Schwartzberg LS, Birch R, et al: Collection of peripheral blood stem cells following the administration of paclitaxel, cyclophosphamide and filgrastim in patients with breast and ovarian cancer. Biol Blood Marrow Transplant 3:83-90, 1997
10. Sheridan WP, Begley CG, Juttner CA, et al: Effect of peripheral-blood progenitor cells mobilized by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 339:640-644, 1992
11. Haas R, Ho AD, Bredthauer U, et al: Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocyte-macrophage colony-stimulating factor. Exp Hematol 18: 94-98, 1990
12. Spitzer G, Adkins D, Mathews M, et al: Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: Effects on hematopoietic recovery after high-dose chemotherapy. Bone Marrow Transplant 20:921-930, 1997
13. Lane TA, Ho AD, Bashey A, et al: Mobilization of blood-derived stem and progenitor cells in normal subjects by granulocyte macrophage and granulocyte-colony stimulating factors. Transfusion 39:39-47, 1999
14. Jagannath S, Vesole DH, Glenn L, et al: Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood 80:1666-1672, 1992
15. Bishop MR, Anderson JR, Jackson JD, et al: High-dose therapy and peripheral blood progenitor cell transplantation: Effects of recombinant human granulocyte-macrophage colony-stimulating factor on the autograft. Blood 83:610-616, 1994
16. Hohaus S, Martin H, Wassmann B, et al: Recombinant human granulocyte and granulocyte macrophage-colony stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells. Bone Marrow Transplant 22:625-630, 1998
17. Winter JN, Lazarus HM, Rademaker A, et al: Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells. J Clin Oncol 14:277-286, 1996
18. Bregni M, Siena S, Di Nicola M, et al: Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy. J Clin Oncol 14:628-635, 1996
19. + cells. Blood 84:2930-2939, 1994
20. Peters W, Rosner G, Ross M, et al: Comparative effects of granulocyte macrophage-colony stimulating factor (GM-CSF) and granulocyte-colony stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 81:1709-1719, 1993
21. Gianni AM, Siena S, Bregni M, et al: Granulocyte macrophage-colony stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 2:580-585, 1989
22. + hematopoietic stem cells in the peripheral blood high-dose cyclophosphamide-treated patients: Enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor. Blood 74: 1905-1914, 1989
23. Alegre A, Tomás J, Martínez-Chamorro C, et al: Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: High-dose cyclophosphamide plus GM-CSF vs G-CSF alone. Bone Marrow Transplant 20:211-217, 1997
24. Handgretinger R, Klingebiel T, Herter M, et al: Comparative analysis of peripheral stem cells collected and transplanted in combination with granulocyte macrophage and granulocyte-colony stimulating factors. Prog Clin Biol Res 389:479-486, 1994
25. Hohaus S, Goldschmidt H, Ehrhardt R, et al: Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF. Exp Hematol 21:508-514, 1993
26. Elias AD, Ayash L, Anderson KC, et al: Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Blood 79:3036-3044, 1992
27. Weaver CH, West WH, Schwartzberg LS, et al: Induction, mobilization of peripheral blood stem cells (PBSC), high-dose chemotherapy and PBSC infusion in patients with untreated stage IV breastcancer: Outcomes by intent to treat analyses. Bone Marrow Transplant 19:661-670, 1997
28. The American Society of Clinical Oncology and American Society of Hematology recommended criteria for the performance of bone marrow transplantation. J Clin Oncol 8:563-564, 1990
29. Weaver CH, Hazelton B, Birch R, et al: An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 86:3961-3969, 1995
30. Weaver CH, Schwartzberg LS, Zhen B, et al: High-dose chemotherapy and peripheral blood stem cell infusion in patients with non-Hodgkin's lymphoma: Results of outpatient treatment in community cancer centers. Bone Marrow Transplant 20:753-760, 1997
31. Weaver CH, Bensinger WI, Appelbaum K, et al: Phase I study of high-dose busulfan, melphalan, thiotepa with autologous stem cell support in patients with refractory malignancies. Bone Marrow Transplant 14:813-819, 1994
32. Weaver CH, Zhen B, Schwartzberg LS, et al: Phase I-II evaluation of rapid sequence tandem high-dose melphalan with peripheral blood stem cell support in patients with multiple myeloma. Bone Marrow Transplant 22:245-251, 1998
33. + content. Bone Marrow Transplant 19:1103-1110, 1997
34. + cell yields. J Hematother 7:241-249, 1998
35. Weaver CH, Schwartzberg LS, Hainsworth J, et al: Treatment related mortality in 1,000 consecutive patients receiving high-dose chemotherapy and peripheral blood progenitor cell transplantation in community cancer centers. Bone Marrow Transplant 19:671-678, 1997
36. Green S, Weiss GR: Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10:239-253, 1992
37. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
38. Peto R, Peto J: Asymptotically efficient rank invariant test procedures. J Royal Stat Soc A 135:185-198, 1972
39. Demirer T, Buckner CD, Storer B, et al: Effect of different chemotherapy regimens on peripheral-blood stem-cell collections in patients with breast cancer receiving granulocyte colony-stimulating factor. J Clin Oncol 15:684-690, 1997
40. Lane TA, Law P, Maruyama M, et al: Mobilization of hematopoietic stem cells into peripheral blood of normal donors by GCSF or GMCSF: Potential role in allogeneic marrow transplantation. Exp Hematol 22:683, 1994
41. + subsets in leukapheresis products mobilized by G-CSF, GM-CSF vs. a combination of both. Exp Hematol 24:1460-1468, 1996
42. Lane TA, Law P, Maruyama M, et al: Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: Potential role in allogeneic marrow transplantation. Blood 85:275-282, 1995
43. + cells in peripheral blood progenitor cell transplants (PBPCT). Proc Am Soc Hematol 90:370a, 1997 (abstr 1646)
44. + cell dose on resource utilization in patients after high-dose chemotherapy with peripheral-blood stem-cell support. J Clin Oncol 17:1227-1233, 1999
45. Beveridge RA, Miller JA, Kales AN, et al: A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression. Cancer Invest 16:366-373, 1998